New drug delivery system to improve cancer treatment
Gold nanoparticles use DNA to deliver anti-cancer drug
Preliminary tests indicate that this delivery device has the potential to improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.
‘The possibilities of this new system are really exciting,’ said Professor James Dabrowiak at Syracuse University. ‘It would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumour drug directly within the tumour.’
These and other upgrades could enable doctors to focus chemotherapy more tightly on cancer cells and reduce side effects on healthy cells in other parts of the body.
A key element of the system is that the DNA attached to the gold particles is engineered to bind to the DOX drug. Studies show that DOX can be transferred by diffusion to a receptor DNA molecule.
The gold nanoparticles have an average diameter of only 15.5nm or a few billionths of a metre. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of particles, could create a massive assault on a tumour, the researchers have found.
‘We believe this work can bring significant gains in the effectiveness of chemotherapy treatments,’ said Mathew Maye, Assistant Professor of Chemistry at Syracuse University and co-inventor of the delivery system. ‘We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools.’
The US FDA has already approved DOX. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.
The Syracuse researchers are continuing investigations to check the toxicity of the system. They will also explore ‘smart’ particles capable of attaching to cancer cells and responding to triggers that will activate drug release.
The work of the Syracuse team is published in a February 2011 issue of ChemComm, published by the Royal Society of Chemistry.
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Read moreHovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Trending Articles
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging